381 related articles for article (PubMed ID: 31431378)
1. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
Zhan M; Zheng H; Yang Y; Xu T; Li Q
Radiother Oncol; 2019 Dec; 141():27-32. PubMed ID: 31431378
[TBL] [Abstract][Full Text] [Related]
2. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus.
Salcedo J; Suen SC; Bian SX
Cancer Med; 2020 Jan; 9(2):440-446. PubMed ID: 31749330
[TBL] [Abstract][Full Text] [Related]
5. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
7. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Guo X; Wang Z; Yang H; Mao T; Chen Y; Zhu C; Yu Z; Han Y; Mao W; Xiang J; Chen Z; Liu H; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Lin T; Liu M; Fu J; Fang W
Ann Surg; 2023 Feb; 277(2):259-266. PubMed ID: 33605586
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
9. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010.
Liu S; Wen J; Yang H; Li Q; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Zhao L; Liu H; Hu Y; Liu M; Fu J; Xi M
Eur J Cancer; 2020 Oct; 138():113-121. PubMed ID: 32877795
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.
Chen D; Kong M; Sun J; Yang H; Chen Y; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Witharana P; Fu J; Chen B; Shen J; Zhu C
J Thorac Cardiovasc Surg; 2023 Mar; 165(3):888-897. PubMed ID: 36137841
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
12. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
15. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis.
Hur C; Choi SE; Kong CY; Wang GQ; Xu H; Polydorides AD; Xue LY; Perzan KE; Tramontano AC; Richards-Kortum RR; Anandasabapathy S
World J Gastroenterol; 2015 May; 21(18):5513-23. PubMed ID: 25987774
[TBL] [Abstract][Full Text] [Related]
16. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
20. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random.
Qian D; Chen X; Shang X; Wang Y; Tang P; Han D; Jiang H; Chen C; Zhao G; Zhou D; Cao F; Er P; Zhang W; Li X; Zhang T; Zhang B; Guan Y; Wang J; Yuan Z; Yu Z; Wang P; Pang Q
Radiother Oncol; 2022 Sep; 174():1-7. PubMed ID: 35764191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]